Results 1 to 10 of about 413,694 (387)

Hepatitis B Vaccines. [PDF]

open access: yesJ Infect Dis, 2021
Abstract Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality.
Pattyn J   +3 more
europepmc   +7 more sources

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab. [PDF]

open access: yesCrohns Colitis 360, 2020
Background Patients with inflammatory bowel disease (IBD) have an elevated risk for infection which is further increased by immunosuppressive medications.
Harrington JE   +4 more
europepmc   +2 more sources

Hepatitis B vaccines

open access: yesJournal of Hepatology, 2003
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
D. Shouval
openaire   +4 more sources

Immunogenicity and Safety of Pneumococcal Vaccines Co-Administered with Common Travel Vaccines in Adults: A Systematic Review [PDF]

open access: yesVaccines
Background: Co-administration of vaccines can impact the immune response and safety. We aim to systematically review the current scientific literature and find evidence regarding the immunogenicity and safety of pneumococcal vaccines co-administered with
Raziyeh Niyati   +4 more
doaj   +2 more sources

Antibody responses to recombinant and plasma derived hepatitis B vaccines. [PDF]

open access: bronzeBritish medical journal, 1986
S E Brown   +4 more
openalex   +2 more sources

Mission 2030: Toward universal hepatitis B immunization [PDF]

open access: yesHuman Vaccines & Immunotherapeutics
Despite the availability of efficacious and safe vaccines for more than 40 years, the rate of new hepatitis B virus (HBV) infections remains high, leaving large populations at risk of developing chronic hepatitis B, liver cirrhosis and cancer.
Elias Broeckhoven, Kai Dallmeier
doaj   +2 more sources

HBV Vaccines: Advances and Development

open access: yesVaccines, 2023
Hepatitis B virus (HBV) infection is a global public health problem that is closely related to liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic HBV infection, liver cirrhosis, and HCC has significantly decreased as ...
Faisal Mahmood   +9 more
doaj   +1 more source

Prevalence of protective antibody levels against hepatitis B infection among healthcare workers in a tertiary care hospital in India

open access: yesAsian Journal of Medical Sciences, 2023
Background: Hepatitis B virus (HBV) infection affects more than 2 billion individuals globally HBV. The chance of dying from liver cirrhosis, acute fulminant liver disease, or hepatocellular carcinoma (HCC) is present in 240 million of these chronic HBV ...
Ramesh Thanikachalam   +2 more
doaj   +1 more source

Neonatal hepatitis B vaccination: Reevaluating timing and adjuvants for enhanced safety and effectiveness

open access: yesPediatric Discovery, 2023
Our aim is an achievement of a 100 percent vaccination rate without toxic vaccine effects. We did a comprehensive literature review on aluminum neurotoxicity and early neonatal hepatitis B vaccination.
Aleksandar Cirovic   +3 more
doaj   +1 more source

METHODS FOR ASSESSMENT OF THE SPECIFIC ACTIVITY OF DRUGS FOR PREVENTION OF HEPATITIS B

open access: yesВопросы вирусологии, 2017
The immunologic activity (specific activity) is one of the main indicators of quality of vaccines for prophylaxis of hepatitis B, along with their safety.
E. L. Postnova   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy